ICBI provides access to a variety of funding sources for translational research, and technology development and commercialization. Indiana CTSI offers milestone-based grant support for assay and model development through the CORE grant, screening and identification of potential drug molecules through the Molecular Therapeutics grant, development of proof of concept for drug, device, cell or gene therapy and diagnostics through the CRT grant and further product development through the Technology Enhancement Award (TEA ). ICBI provides support and guidance for SBIR/STTR applications and connections to angel and venture capital investors.
The Indiana Clinical and Translational Sciences Institute (CTSI) and Indiana University offer a variety of funding opportunities that are open to IUSM researchers. These include funding for basic research and clinical trials as well as specialized opportunities for equipment.
Technology Enhancement Award (TEA)
The Indiana CTSI and Indiana University School of Medicine (IUSM) in partnership with the Indiana Center for Biomedical Innovation (ICBI) are offering translational research funding for the advancement of early-stage technologies to commercialization. The Technology Enhancement Awards (TEA) will be available to faculty and postdocs from IUSM. The funding will be used for generating supporting data necessary for preparation of SBIR/STTR grant applications. The technologies may include highly promising therapeutics (small molecule or biologics), diagnostics or biomedical devices. , please click on the Technology Enhancement Award RFA_2018. Submission deadline September 4th, 2018. TEA RFA guidelines.2018
The Indiana Clinical and Translational Sciences Institute (Indiana-CTSI) is offering a unique opportunity to postdocs for an appointment as an ICBI fellow at the Indiana Center for Biomedical Innovation (ICBI). All postdocs currently pursuing research at the CTSI partner institutions (IUSM, IU, Purdue, IUPUI, Notre Dame) are eligible to apply for the ICBI fellow position. The ICBI fellow will receive directed training in translational research and entrepreneurship. The ICBI fellow will undertake a project involving research on the development of life sciences technology pertaining to human health and disease. The project could include research on the development of therapies, diagnostics, or medical devices. The ICBI fellow will work in an entrepreneurial ecosystem at ICBI. The position will have significant opportunity to work with startup companies and access to private sector companies including, pharmaceutical and medical device companies. ICBI and its startup companies are conducting research on a wide range of biomedical topics. The training is on experiential research, supplemented with seminars and invited talks that will help the fellow consider a scientific career in the industry. The ICBI fellow will participate in grant writing and publications. The ICBI fellow position is a one-year in duration with the option to re-apply for a second year. Submission deadline September 5th, 2018 online application: ICBI Fellow ; ICBI Fellow RFA guidelines 2018
Medical Device Development Award (MDDA)
In partnership with the Indiana CTSI, the Indiana Center for Biomedical Innovation (ICBI) supports the development of nascent medical device technologies invented by IU School of Medicine Staff (clinical & non-clinical) and Indiana CTSI-affiliated engineers by providing advice and assistance through the Medical Device Development Assistance (MDDA) program. Selected participants will receive mentorship support through the ICBI Advisory Council and the SPARK-Stanford partnership.
Indiana Drug Discovery Alliance (IDDA)
The Indiana Drug Discovery Alliance (IDDA) aims to promote and support promising early-stage drug discovery research in Indiana. IDDA facilitates collaborative translational research and partnerships through identification of complementary expertise and support for team building across diverse disciplines. Small grants are available to support new collaborations and/or the use of core facilities that enable the translation of fundamental discoveries related to drug discovery. Submission Deadline June 4, 2018
Strategic Pharma-Academic Research Consortium (SPARC) Awards Program
The Midwest Strategic Pharma-Academic Research Consortium (SPARC) is a group of universities and pharmaceutical companies dedicated to addressing research challenges facing the pharmaceutical industry. The research is in the non-competitive space of mutual interest that addresses scientific and technological research challenges confronting the pharmaceutical industry. SPARC’s founding members are Indiana University, Northwestern University, Ohio State University, Washington University in St. Louis, Eli Lilly and Company, and Takeda Pharmaceuticals
GSK Discovery Fast Track Challenge
The Discovery Fast Track Challenge is a challenge that recognizes and rewards innovative concepts, discoveries, and research by investigators at U.S. and Canadian research institutions, colleges, and universities. Winning investigators will collaborate with a team of GSK scientists to put their innovative research concept on an accelerated drug discovery path.
Johnson & Johnson Innovation Centers
The Johnson & Johnson Innovation Centers catalyze, support, and invest in highly differentiated early-stage innovations. The Centers bring together resources from across the company to meet the needs of entrepreneurs and scientists developing the important medical device and diagnostic technologies, consumer health care products, and pharmaceuticals.
Lilly Open Innovation Drug Discovery
The Lilly Open Innovation Drug Discovery platform provides access to internal screening assays for external investigators as an in-kind contribution to their research.
Pfizer Centers for Therapeutic Innovation
The Pfizer Centers for Therapeutic Innovation partner with academic medical centers and disease foundations to translate research ideas into clinical applications, offering funding and resources to principal investigators and postdocs at academic medical centers to continue development and research on a promising therapeutic or hypothesis. Throughout the year, CTI issues call for proposals to academic medical centers.